Table 2.
National Comprehensive Cancer Network (NCCN) guideline-based cancer surveillance completed as a direct result of cascade genetic testing (N = 25 relatives with pathogenic variants)
Recommendation for cancer screening | N | % | |
---|---|---|---|
Relatives not recommended cancer screening | 7 | ||
Relatives recommended cancer screening | 18 | ||
Completed ≥1 screening | 13 | 72.2 | |
Completed all recommended screening | 6 | 33.3 | |
Completed none of the recommended screening | 5 | 27.8 | |
Screening interventions | # Relatives recommended | # Relatives completed | % |
Mammogram | 10 | 7 | 70.0 |
Breast magnetic resonance imaging (MRI) | 10 | 3 | 30.0 |
Prostate specific antigen screening | 1 | 1 | 100.0 |
Colonoscopy | 5 | 4 | 80.0 |
Measured NCCN-based cancer screening interventions by mutation: BRCA1 – mammogram, breast MRI; BRCA2 – mammogram, breast MRI, prostate specific antigen for males; CHEK2 – mammogram, breast MRI, colonoscopy; APC I1307K variant – colonoscopy.